Search

Your search keyword '"Ossenkoppele, G J"' showing total 566 results
Start Over Author "Ossenkoppele, G J"
566 results on '"Ossenkoppele, G J"'

1. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial

Author

van de Loosdrecht, A. A., Cremers, E. M. P., Alhan, C., Duetz, C., in ’t Hout, F. E. M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J. W. M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M. C., de Greef, G. E., te Boekhorst, P. A. W., Raaijmakers, M. H. G., van Marwijk Kooy, M., Legdeur, M. C., Wegman, J. J., Deenik, W., de Weerdt, O., van Maanen-Lamme, T. M., Jobse, P., van Kampen, R. J. W., Beeker, A., Wijermans, P. W., Biemond, B. J., Tanis, B. C., van Esser, J. W. J., Schaar, C. G., Noordzij-Nooteboom, H. S., Jacobs, E. M. G., de Graaf, A. O., Jongen-Lavrencic, M., Stevens-Kroef, M. J. P. L., Westers, T. M., and Jansen, J. H.

Published
2024
Full Text
View/download PDF

2. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

Author

Janssen, J. J. W. M., Löwenberg, B., Manz, M., Biemond, B. J., Westerweel, P. E., Klein, S. K., Fehr, M., Sinnige, H. A. M., Efthymiou, A., Legdeur, M. C. J. C., Pabst, T., Gregor, M., van der Poel, M. W. M., Deeren, D., Tick, L. W., Jongen-Lavrencic, M., van Obbergh, F., Boersma, R. S., de Weerdt, O., Chalandon, Y., Heim, D., Spertini, O., van Sluis, G., Graux, C., Stüssi, G., van Norden, Y., and Ossenkoppele, G. J.

Published
2022
Full Text
View/download PDF

3. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes:the HOVON89 trial

Author

van de Loosdrecht, A. A., Cremers, E. M.P., Alhan, C., Duetz, C., in ’t Hout, F. E.M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J.W.M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M.C., de Greef, G. E., te Boekhorst, P. A.W., Raaijmakers, M. H.G., van Marwijk Kooy, M., Legdeur, M. C., Wegman, J. J., Deenik, W., de Weerdt, O., van Maanen-Lamme, T. M., Jobse, P., van Kampen, R. J.W., Beeker, A., Wijermans, P. W., Biemond, B. J., Tanis, B. C., van Esser, J. W.J., Schaar, C. G., Noordzij-Nooteboom, H. S., Jacobs, E. M.G., de Graaf, A. O., Jongen-Lavrencic, M., Stevens-Kroef, M. J.P.L., Westers, T. M., Jansen, J. H., van de Loosdrecht, A. A., Cremers, E. M.P., Alhan, C., Duetz, C., in ’t Hout, F. E.M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J.W.M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M.C., de Greef, G. E., te Boekhorst, P. A.W., Raaijmakers, M. H.G., van Marwijk Kooy, M., Legdeur, M. C., Wegman, J. J., Deenik, W., de Weerdt, O., van Maanen-Lamme, T. M., Jobse, P., van Kampen, R. J.W., Beeker, A., Wijermans, P. W., Biemond, B. J., Tanis, B. C., van Esser, J. W.J., Schaar, C. G., Noordzij-Nooteboom, H. S., Jacobs, E. M.G., de Graaf, A. O., Jongen-Lavrencic, M., Stevens-Kroef, M. J.P.L., Westers, T. M., and Jansen, J. H.

Abstract

A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70.7 months. In arm A and B, 39 and 41% of patients achieved HI-E; median time-to-HI-E: 3.2 months for both arms, median duration of-HI-E: 9.8 months. HI-E was significantly lower in non-del(5q) vs. del(5q): 32% vs. 80%. The same accounted for transfusion independency-at-week 24 (16% vs. 67%), but similar in both arms. Apart from presence of del(5q), high percentages of bone marrow lymphocytes and progenitor B-cells, a low number of mutations, absence of ring sideroblasts, and SF3B1 mutations predicted HI-E. In conclusion, lenalidomide induced HI-E in patients with non-del(5q) and del(5q) MDS without additional effect of ESA/G-CSF. The identified predictors of response may guide application of lenalidomide in lower-risk MDS in the era of precision medicine. (EudraCT 2008-002195-10).

Published
2024

5. Leukemieën en myelodysplasie

Author

Ossenkoppele, G. J., Cornelissen, J. J., Sonneveld, P., van de Velde, C.J.H., editor, van der Graaf, W.T.A., editor, van Krieken, J.H.J.M., editor, and Marijnen, C.A.M., editor

Published
2017
Full Text
View/download PDF

7. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Author

Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., and Löwenberg, B.

Published
2020
Full Text
View/download PDF

13. In-Vitro Cellular Drug Resistance in Acute Non-Lymhoblastic Leukemia: Comparisons Between Adults and Children

Author

De Haas, T. G. K. J., Zwaan, Ch. M., Wondergem, M. J., Pieters, R., Kaspers, G. J. L., Loonen, A. H., Rottier, M. M. A., WüNsche, R., Creutzig, U., Bartl, S., HäHlen, K., Broxterman, Hj., Ossenkoppele, G. J., Veerman, A. J. R., Büchner, T., editor, Hiddemann, W., editor, Wörmann, B., editor, Schellong, G., editor, Ritter, J., editor, and Creutzig, U., editor

Published
2001
Full Text
View/download PDF

17. S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE

Author

Hernández-Sánchez, A., primary, Villaverde-Ramiro, Á., additional, Martínez Elicegui, J., additional, González, T., additional, Benner, A., additional, Sträng, E., additional, Castellani, G., additional, Heckman, C. A., additional, Versluis, J., additional, Abáigar, M., additional, Sobas, M., additional, Azibeiro, R., additional, Tur, L., additional, Valk, P. J., additional, Metzeler, K. H., additional, Ayala, R., additional, Dall’Olio, D., additional, Tettero, J., additional, Martínez-López, J., additional, Dombret, H., additional, Pratcorona, M., additional, Damm, F., additional, Mills, K. I., additional, Mayer, J., additional, Thiede, C., additional, Voso, M. T., additional, Sanz, G. F., additional, Calado, F., additional, Döhner, K., additional, Gaidzik, V. I., additional, Heuser, M., additional, Haferlach, T., additional, Turki, A. T., additional, Reinhardt, D., additional, Villoria Medina, R., additional, van Speybroeck, M., additional, Schulze-Rath, R., additional, Barbus, M., additional, Butler, J. E., additional, Hernández Rivas, J. M., additional, Huntly, B. J., additional, Ossenkoppele, G. J., additional, Döhner, H., additional, and Bullinger, L., additional

Published
2022
Full Text
View/download PDF

18. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, Carlos, Stüssi, G, van Norden, Y, Ossenkoppele, G J, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, Carlos, Stüssi, G, van Norden, Y, and Ossenkoppele, G J

Abstract

Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML patients > 65 years of age (median 69 (65-80)) were randomly assigned to standard chemotherapy (3 + 7) with or without oral selinexor 60 mg twice weekly (both arms n = 51), days 1-24. In the second cycle, cytarabine 1000 mg/m twice daily, days 1-6 with or without selinexor was given. CR/CRi rates were significantly higher in the control arm than in the investigational arm (80% (95% C.I. 69-91%) vs. 59% (45-72%; p = 0.018), respectively). At 18 months, event-free survival was 45% for the control arm versus 26% for the investigational arm (Cox-p = 0.012) and overall survival 58% vs. 33%, respectively (p = 0.009). AML and infectious complications accounted for an increased death rate in the investigational arm. Irrespective of treatment, MRD status after two cycles appeared to be correlated with survival. We conclude that the addition of selinexor to standard chemotherapy does negatively affect the therapeutic outcome of elderly AML patients. (Netherlands Trial Registry number NL5748 (NTR5902), www.trialregister.nl ).

Published
2022

27. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

Author

Kiesewetter, B., Cherny, N. I., Boissel, Nicolas, Cerisoli, F., Dafni, U., De Vries, Elisabeth G. E., Ghia, Paolo, Gökbuget, N., González-Calle, Verónica, Huntly, B., Jäger, U., Latino, N. J., Douillard, Jean-Yves, Malcovati, L., Mateos, M. V., Ossenkoppele, G. J., Porkka, K., Raderer, M., Ribera, Jose-Maria, Scarfò, L., Wester, R., Zygoura, P., Sonneveld, P., Universitat Autònoma de Barcelona, Hematology, Radiotherapy, CCA - Cancer Treatment and quality of life, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Kiesewetter, Barbara [0000-0002-5490-2371], Apollo - University of Cambridge Repository, Kiesewetter, B., Cherny, N. I., Boissel, N., Cerisoli, F., Dafni, U., De Vries, E. G. E., Ghia, P., Gokbuget, N., Gonzalez-Calle, V., Huntly, B., Jager, U., Latino, N. J., Douillard, J. -Y., Malcovati, L., Mateos, M. -V., Ossenkoppele, G. J., Porkka, K., Raderer, M., Ribera, J. -M., Scarfo', L., Wester, R., Zygoura, P., Sonneveld, P., HUS Comprehensive Cancer Center, Hematologian yksikkö, and Helsinki University Hospital Area

Subjects
Cancer Research, medicine.medical_specialty, 3122 Cancers, value frameworks, ESMO-MCBS, Haematologic malignancies, Chronic lymphatic leukemia, Clinical benefit, 03 medical and health sciences, 0302 clinical medicine, QUALITY-OF-LIFE, Rating scale, Chronic leukaemia, REFRACTORY MULTIPLE-MYELOMA, Outcome Assessment, Health Care, medicine, Hematologic malignancy, Humans, ddc:610, Intensive care medicine, Grading (tumors), Societies, Medical, Original Research, 030304 developmental biology, RISK MYELODYSPLASTIC SYNDROMES, Solid tumour, 0303 health sciences, haematologic malignancies, business.industry, CHRONIC LYMPHOCYTIC-LEUKEMIA, Value frameworks, Myelodysplastic syndromes, clinical benefit, STEM-CELL TRANSPLANTATION, medicine.disease, LITY-OF-LIFE, 3. Good health, Clinical trial, LOW-DOSE CYTARABINE, Oncology, 030220 oncology & carcinogenesis, Hematologic Neoplasms, BORTEZOMIB-MELPHALAN-PREDNISONE, TRANSFUSION-DEPENDENT PATIENTS, OBINUTUZUMAB PLUS BENDAMUSTINE, business, NON-HODGKIN-LYMPHOMA
Abstract

OBJECTIVE: Value frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS).METHODS: Here we present the results of the first feasibility testing of the ESMO-MCBS v1.1 for haematological malignancies based on the grading of 80 contemporary studies for acute leukaemia, chronic leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The aims were (1) to evaluate the scorability of data, (2) to evaluate the reasonableness of the generated grades for clinical benefit using the current version and (3) to identify shortcomings in the ESMO-MCBS v1.1 that require amendments to improve the efficacy and validity of the scale in grading new treatments in the management of haematological malignancies.RESULTS: In general, the ESMO-MCBS v1.1 was found to be widely applicable to studies in haematological malignancies, generating scores that were judged as reasonable by European Hematology Association (EHA) experts. A small number of studies could either not be graded or were not appropriately graded. The reasons, related to the differences between haematological and solid tumour malignancies, are identified and described.CONCLUSIONS: Based on the findings of this study, ESMO and EHA are committed to develop a version of the ESMO-MCBS that is validated for haematological malignancies. This development process will incorporate all of the usual stringencies for accountability of reasonableness that have characterised the development of the ESMO-MCBS including field testing, statistical modelling, evaluation for reasonableness and openness to appeal and revision. Applying such a scale will support future public policy decision-making regarding the value of new treatments for haematological malignancies and will provide insights that could be helpful in the design of future clinical trials.

Published
2020
Full Text
View/download PDF

47. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia: A study of 6,515 cases of AML: V27

Author

Gröschel, S., Lugthart, S., Beverloo, B. H., Kayser, S., Valk, P. J., Van Zelderen-Bhola, S. L., Ossenkoppele, G.-J., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., Verhoef, G., Ferrant, A., Köhne, C.-H., Pfreundschuh, M., Horst, H.-A., Koller, E., von Lilienfeld-Toal, M., Bentz, M., Ganser, A., Schlegelberger, B., Jotterand, M., Krauter, J., Pabst, T., Theobald, M., Schlenk, R. F., Delwel, R., Döhner, K., Löwenberg, B., and Döhner, H.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results